Currently out of the existing stock ratings of Jeffrey Hung, 72 are a HOLD (43.64%), 15 are a SELL (9.09%), 78 are a BUY (47.27%).

Jeffrey Hung

Work Performance Price Targets & Ratings Chart

Analyst Jeffrey Hung, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 59.08% that have a potential upside of 24.76% achieved within 138 days.

Jeffrey Hung’s has documented 335 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 07-Aug-2024.

Wall Street Analyst Jeffrey Hung

Analyst best performing recommendations are on RYTM (RHYTHM PHARMACEUTICALS).
The best stock recommendation documented was for RYTM (RHYTHM PHARMACEUTICALS) at 11/9/2022. The price target of $26 was fulfilled within 2 days with a profit of $3.75 (16.85%) receiving and performance score of 84.27.

Average potential price target upside

of $85.66 (44.39%) on KRTX (KARUNA THERAPEUTICS).
of $20.85 (21.26%) on NBIX (NEUROCRINE BIOSCIENCES).
of $19.56 (32.45%) on ITCI (INTRACELLULAR TH).

ACAD ACADIA Pharmaceuticals CYTK Cytokinetics ESPR Esperion Therapeutics EVFM Evofem Biosciences EXEL Exelixis PRLD Prelude Therapeutics RARE Ultragenyx VYGR Voyager Therapeutics APRE Aprea Therapeutics BCYC Bicycle Therapeutics Ltd JAZZ Jazz Pharmaceuticals PLC MYOK MyoKardia NBIX Neurocrine Biosciences NXTC NextCure RPTX Repare Therapeutics CELU Celularity CGEM Cullinan Oncology LLC CINC CinCor Pharma GRPH Graphite Bio RUBY Rubius Therapeutics CYT Cyteir Therapeutics RYTM Rhythm Pharmaceuticals XLRN Acceleron Pharma ERAS Erasca IMRX Immuneering Corp ITCI Intracellular Th KRTX Karuna Therapeutics PTCT PTC Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

David Hoang (CITI)